Sabestomig
Phase 1Biologic
Sabestomig is one of 54 biologic programs targeting Cancer. It is currently in Phase 1.
1
Indications
3
Total Trials
1
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
57 competitors in Cancer
#DrugCompanyPhaseTrials
1Vemlidy
GileadApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Tecentriq
RochePhase 2
Keytruda
Merck & Co.Phase 2
Afinitor
NovartisPhase 2
Cotellic
RochePhase 2
Verzenio
Eli LillyPhase 2
Stivarga
BayerPhase 2
Imfinzi
AstraZenecaPhase 2
Erivedge
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sabestomig. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- PPresage Biosciences